EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity

Jack Y Lee, Bianca Nguyen, Anandaroop Mukhopadhyay, Mia Han, Jun Zhang, Ravindra Gujar, Jon Salazar, Reneta Hermiz, Lauren Svenson, Erica Browning, H Kim Lyerly, David A Canton und 5 weitere

Molecular Therapy - Oncolytics · 2022-06 · 25 · 174-188

DOI: 10.1016/j.omto.2022.04.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy - Oncolytics, 2022-06. Verfasst von Jack Y Lee und 16 weiteren Autor:innen. Beteiligte Einrichtung: Oncosec Medical Incorporated, 3565 General Atomics Court, San Diego, CA 92121, USA. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical studies have demonstrated that local expression of the cytokine IL-12 drives interferon-gamma expression and recruits T cells to the tumor microenvironment, ultimately yielding durable systemic T cell responses. Interrogation of longitudinal biomarker data from our late-stage melanoma trials identified a significant on-treatment increase of intratumoral CXCR3 transcripts that was restricted to responding patients, underscoring the clinical relevance of tumor-infiltrating CXCR3+ immune cells. In this study, we sought to understand if the addition of DNA-encodable CXCL9 could augment the anti-tumor immune responses driven by intratumoral IL-12. We show that localized IL-12 and CXCL9 treatment reshapes the tumor microenvironment to promote dendritic cell licensing and CD8+ T cell activation. Additionally, this combination treatment results in a significant abscopal anti-tumor response and provides a concomitant benefit to anti-PD-1 therapies. Collectively, these data demonstrate that a functional tumoral CXCR3/CXCL9 axis is critical for IL-12 anti-tumor efficacy. Furthermore, restoring or amplifying the CXCL9 gradient in the tumors via intratumoral electroporation of plasmid CXCL9 can not only result in efficient trafficking of cytotoxic CD8+ T cells into the tumor but can also reshape the microenvironment to promote systemic immune response.

Schlagwörter

Stichwörter der Autor:innen

4T1CT26CXCL9CXCR3DNA-encodableIL-12anti-PD-1chemotaxiselectroporationtavokinogene telseplasmid

Autor:innen und Institutionen

  • Oncosec Medical Incorporated, 3565 General Atomics Court, San Diego, CA 92121, USA.
  • Department of Immunology, Duke University, Durham, NC 27710, USA.
  • Department of Immunology, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263, USA.
  • Department of Medicine, University of California, San Francisco, 550 16 Street, San Francisco, CA 94158, USA.

Zitieren

APA

Lee, J. Y., Nguyen, B., Mukhopadhyay, A., Han, M., Zhang, J., Gujar, R., Salazar, J., Hermiz, R., Svenson, L., Browning, E., Lyerly, H. K., Canton, D. A., Fisher, D., Daud, A., Algazi, A., Skitzki, J., & Twitty, C. G. (2022). Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity. Molecular Therapy - Oncolytics, 25, 174-188. https://doi.org/10.1016/j.omto.2022.04.005

Vancouver

Lee JY, Nguyen B, Mukhopadhyay A, Han M, Zhang J, Gujar R, et al. Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity. Molecular Therapy - Oncolytics. 2022;25:174-188. doi:10.1016/j.omto.2022.04.005

BibTeX
@article{Lee2022,
  author = {Lee, Jack Y and Nguyen, Bianca and Mukhopadhyay, Anandaroop and Han, Mia and Zhang, Jun and Gujar, Ravindra and Salazar, Jon and Hermiz, Reneta and Svenson, Lauren and Browning, Erica and Lyerly, H Kim and Canton, David A and Fisher, Daniel and Daud, Adil and Algazi, Alain and Skitzki, Joseph and Twitty, Christopher G},
  title = {Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity},
  journal = {Molecular Therapy - Oncolytics},
  year = {2022},
  volume = {25},
  pages = {174--188},
  doi = {10.1016/j.omto.2022.04.005}
}
Kostenlos starten →